Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
2.380
-0.110 (-4.42%)
Oct 13, 2025, 4:00 PM EDT - Market closed
Caribou Biosciences Revenue
Caribou Biosciences had revenue of $2.67M in the quarter ending June 30, 2025, a decrease of -23.01%. This brings the company's revenue in the last twelve months to $9.12M, down -72.45% year-over-year. In the year 2024, Caribou Biosciences had annual revenue of $9.99M, down -71.01%.
Revenue (ttm)
$9.12M
Revenue Growth
-72.45%
P/S Ratio
23.96
Revenue / Employee
$62,048
Employees
147
Market Cap
221.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.99M | -24.48M | -71.01% |
| Dec 31, 2023 | 34.48M | 20.63M | 148.91% |
| Dec 31, 2022 | 13.85M | 4.25M | 44.31% |
| Dec 31, 2021 | 9.60M | -2.76M | -22.35% |
| Dec 31, 2020 | 12.36M | 6.57M | 113.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CRBU News
- 7 weeks ago - Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference - GlobeNewsWire
- 2 months ago - Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference - GlobeNewsWire
- 6 months ago - Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs - GlobeNewsWire
- 6 months ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Connect - Accesswire
- 6 months ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Reach Out - Accesswire